Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Chinese Participants

NCT07528703 is registered in ClinicalTrials.gov with Nanjing Reju Therapeutics Co., Ltd as lead sponsor.

NCT NCT07528703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07528703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Chinese Participants
Lead sponsor
Nanjing Reju Therapeutics Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ipf